SPARK team launches clinical COVID-19 biomarker study
Posted on March 17th, 2021
A SPARK group is now enrolling patients and healthy controls in a clinical study at Stanford to understand the impact of SARS-CoV-2 on cardiovascular and immune systems.
Led by SPARK co-director Kevin Grimes, the research study will measure levels of specific cardiovascular and immune biomarkers believed to be impacted by SARS-CoV-2 infection.
By measuring these indicators, the team hopes to better predict the clinical course of COVID-19, help predict which patients are likely to get worse, help guide treatment strategies, and inform development of new therapies. Participants must be 18-80 years old and have taken a SARS-CoV-2 RNA test within the last 5 days, with confirmed positive or negative results.
For more information on the study and enrollment eligibility, visit the study’s page here.
see studypages.com/s/study-of-effects-of-sars-cov-2-on-the-cardiovascular-and-immune-system-778819/
Permalink: https://sparkmed.stanford.edu/spark-team-launches-clinical-covid-19-biomarker-study/